The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. (Q50124678)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Keith R. Abrams

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

A J Wailoo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

N J Cooper

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

A J Sutton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

K G Nicholson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

6 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

1035-1043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Vaccines for preventing influenza in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Influenza burden of illness: estimates from a national prospective survey of household contacts in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Influenza pneumonia: a descriptive study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Rimantadine prophylaxis in children: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Efficacy of sequential annual vaccination with inactivated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

The effectiveness of vaccination against influenza in healthy, working adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Economic evaluation of strategies for the control and management of influenza in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Economic evaluation of vaccination against influenza in New Zealand.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Economic evaluation of influenza vaccination. Assessment for The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-effectiveness study on influenza prevention in Hong Kong.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-effectiveness of the influenza vaccine in a healthy, working-age population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Effectiveness and cost-benefit of an influenza vaccination program for health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Sickness absence following a campaign of vaccination against influenza in the workplace

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

French economic evaluations of influenza and influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Prevention and early treatment of influenza in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Influenza vaccination among healthy employees: a cost-benefit analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.033

10.1016/J.VACCINE.2004.12.033

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16183177%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference